University of Kentucky

UKnowledge
Molecular and Cellular Biochemistry Faculty
Patents

Molecular and Cellular Biochemistry

11-22-2005

Seventeen Amino Acid Peptide (Peptide P) for Treating Ischemia
and Reperfusion Injury
Peter R. Oeltgen
University of Kentucky, peter.oeltgen@uky.edu

Mark S. Kindy
University of Kentucky

Follow this and additional works at: https://uknowledge.uky.edu/biochem_patents
Part of the Medical Biochemistry Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Oeltgen, Peter R. and Kindy, Mark S., "Seventeen Amino Acid Peptide (Peptide P) for Treating Ischemia
and Reperfusion Injury" (2005). Molecular and Cellular Biochemistry Faculty Patents. 21.
https://uknowledge.uky.edu/biochem_patents/21

This Patent is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge.
It has been accepted for inclusion in Molecular and Cellular Biochemistry Faculty Patents by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

US006967192B2

(12) United States Patent
Oeltgen et al.

(54)

(10) Patent No.:

US 6,967,192 B2

(45) Date of Patent:

SEVENTEEN AMINO ACID PEPTIDE
(PEPTIDE P) FOR TREATING ISCHEMIA

(51)
(52)

Int. Cl.7 ....................... .. A61K 38/00; A61K 38/04
US. Cl. ........................... .. 514/12; 514/13; 514/16;

(58)

Field of Search ............................ .. 514/12, 13, 16,

AND REPERFUSION INJURY
_

Nov. 22, 2005

514/2; 530/300; 530/326

(75) IIIVGIIIOI‘SZ Peter R. Oeltgen, Winchester, KY

514/2. 530/300 350 326

(US); Mark S. Kindy, Lexington, KY

(Us)

’

(56)

(73) Assignee: University of Kentucky Research
Notice:

’

References Cited
US. PATENT DOCUMENTS

Foundation LeXin ton KY US
’
g ’
( )
(,F)

’

Subject to any disclaimer, the term ofthis

6,294,519 B1
6,544,950 B1 *

patent is extended or adjusted under 35

* Cited by examiner

9/2001 Oeltgen et 211.
4/2003 Oeltgen et a1. ............. .. 514/13

U.S.C. 154(b) by 62 days.

(22) Filed:

Mar. 11, 2003

Primary Examiner—Christ0pher R. Tate
Assistant Examiner—B. Dell Chisrn
(74) Attorney, Agent, or Firm—McDerrn0tt Will & Emery
LLP

(65)

Prior Publication Data

(57)

(21) APPL NO; 10/384,650

Us 2003/0211998 A1 NOV' 13’ 2003

ABSTRACT

Peptide P, having the amino acid sequence Tyr-D-Ala-Phe

Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-His-Ser-Ile
Related US‘ Application Data
62

NH2-SEQ ID NO:1, is useful to treat ischernia.

Division of a PP lication No. 10/003,328, ?led on Dec. 6,

2001, now Pat. No. 6,544,950.

17 Claims, 1 Drawing Sheet

U.S. Patent

Nov. 22,2005

US 6,967,192 B2

mectofl’epddo-P (11 mm volmmmlgombml mm

warg
1

VI(%)no?lmct

US 6,967,192 B2
1

2

SEVENTEEN AMINO ACID PEPTIDE

tive amount of Peptide P to said mammal. The ischemic
tissue may be brain, spinal cord or heart.
The present invention is also directed to a method of

(PEPTIDE P) FOR TREATING ISCHEMIA
AND REPERFUSION INJURY

reducing the effect of an ischemic episode comprised of
administering an effective amount of pharmaceutically

This application is a divisional of application Ser. No.
10/003,328 ?led Dec. 6, 2001, now US. Pat. No. 6,544,950.
FIELD OF THE INVENTION
The invention relates to the use of a novel seventeen

amino acid peptide to treat cerebral ischemia and ischemic

10

heart disease including reperfusion injury.
BACKGROUND

Tissues deprived of blood and oxygen undergo ischemic

15

necrosis or infarction With possible irreversible organ dam
age. Cerebral ischemia results from decreased blood and

BRIEF DESCRIPTION OF THE DRAWING
20

The sole ?gure accompanying the application is a graph
shoWing the effect of Peptide-P on infarct volume folloWing

in most cases, some degree of brain damage. The decreased
blood How may be due to, for example, an occlusion such as
a thrombus or embolus, vessel rupture, sudden fall in blood
pressure, change in the vessel lumen diameter due to

atherosclerosis, trauma, aneurysm, developmental

loWer doses in the range of about 1 mg/kg body Weight to

about 1000 mg/kg body Weight of the mammal. Preferably,

oxygen ?oW implicating one or more of the blood vessels of

malformation, altered permeability of the vessel Wall or
increased viscosity or other quality of the blood. Decreased
blood How may also be due to failure of the systemic
circulation and severe prolonged hypotension. Ischemic
necrosis of the spinal cord may result in sensory or motor

body Weight to about 20 mg/kg body Weight, or alternatively
the mammal is human.

the brain. In cerebral ischemia, the individual suffers a stroke

With sudden development of a focal neurologic de?cit and,

effective amount of Peptide P to said mammal.
The present invention is also directed to a method of
treating cerebral or spinal cord ischemia or ischemic heart
disease in a mammal comprised of administering an effec
tive amount of pharmaceutically effective amount of Peptide
P to said mammal.
Preferably, Peptide P is administered as a pharmaceutical
composition at a dosage in the range of about 0.5 mg/kg

cerebral ischemia. Peptide-P at a concentration of 4 mg/Kg
Was injected (IV) 1 hr after occlusion of the external carotid
25

artery (ECA). Controls Were injected With 100 pl of physi
ological saline. Ischemic volume Was assessed after 24 hrs
of reperfusion. Treated animals shoWed a decrease in infarct

30

volume, p<0.006 compared to saline controls. Control had
infarct siZe of 34.45+/—3.6% and Peptide-P had 16.87+/—
3.3%.

symptoms or both that can be referred to cervical, thoracic

or lumbar levels of the spine. Ischemic heart disease results
from an imbalance betWeen myocardial oxygen supply and
demand. In ischemic heart disease, the individual suffers
angina pectoris, acute myocardial infarction or sudden
death. The imbalance may be caused by, for example,

DESCRIPTION OF THE INVENTION

35

atherosclerotic obstruction of one or more large coronary

arteries, nonatheromatous coronary obstructive lesions such
as embolism, coronary ostial stenosis associated With luetic

aortitis, coronary artery spasm, congenital abnormalities of
the coronary circulation, increased myocardial oxygen
demands exceeding the normal supply capabilities as in
severe myocardial hypertrophy, reduction in the oxygen

40

discloses methods for treating ischemia by administering
certain Deltorphin peptides. The publication by LaZarus et
al., “Environmental Health Perspectives”, Vol. 102, No. 4,
pages 648—654 (1994), discloses naturally occurring opiod

type available from Applied Biosystem. Peptide P has the
amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser
Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 and a MW of
1860.1 With alanine as D-isomer. The peptide P can be
produced by a number of methods, such as by use of an

automated peptide synthesiZer, through recombinant
molecular biology techniques, or isolated from a naturally
occurring source.
Peptide P can be administered to ameliorate or inhibit

carrying capacity of the blood such as n anemia, or as a

consequence of inadequate cardiac perfusion pressure due to
hypotension from any cause. US. Pat. No. 6,294,579 B1

Peptide P is a linear 17 amino acid peptide Which has been
synthesiZed on a commercial peptide synthesiZer such as the

45

damage caused by a stroke. A stroke is the acute neurologic
injury caused by one of several pathologic processes involv
ing the blood vessels of the brain. The pathologic process

may be intrinsic to the vessel itself such as in
arteriosclerosis, or may originate from a remote location
50 such as an embolus, or may result from decreased perfusion

or increased blood viscosity With inadequate cerebral blood

peptides.

?oW, or may result from the rupture of a vessel in the

Current treatments for ischemia encompass behavioral

subarachnoid space or intracerebral tissue.
changes drug therapy, and/or surgical intervention. Drugs
The main causes of ischemic stroke are thrombosis,
are frequently preferred before resorting to invasive proce
vasoconstriction and embolism. Diagnosis of a stroke can be
55
dures and to provide more immediate relief than long-term

readily made by one of ordinary skill in the art. Signs of

behavioral changes. Thus, there is a need for a therapeutic
agent Which can be useful in treating or preventing ischemia.

stroke include paralysis, slurred speech, general confusion,
impairment of gait, cortical sensory loss over toes, foot and
leg and urinary incontinence, to name just a feW. The

SUMMARY OF THE INVENTION
60

diagnosis can be con?rmed by cerebral angiography and by

It is an object of the invention to provide a novel peptide
and use of that peptide to treat ischemia.

a computed axial tomography (CT) scan of the brain.

The present invention meets the object by providing a
novel seventeen amino acid peptide (Peptide P) Which is
useful for treating cerebral ischemia and ischemic heart

injury to the brain. The ideal mode of administration is by
intravenous (IV) or intraperitoneal (I.P.) injection at a dose
of about 0.5—20 mg/kg, or alternatively, loWer doses of about
1—1000 mg/kg. Peptide P can also be administered by
subcutaneous or intraarterial injection into the carotid artery,

disease. Also provided is a method of treating ischemia in a

mammal comprised administering a pharmaceutically effec

If a stroke occurs, Peptide P can be administered to limit

65
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or by direct injection into the brain, e.g., intracerebroven
tricular injection (ICV) for dispersion into other areas.
Very often a stroke is caused by a cerebral embolism, the
likelihood of Which can frequently be predicted. In these

leading to ventricular tachycardia or ventricular ?brillation.
Stress tests and coronary arteriography may also provide
diagnostic information. These diagnostic test results may
determine the need for Peptide P administration.

cases, the Peptide P can be administered prophylactically to
prevent or lessen the amount of brain tissue injured during
such an event. Many types of heart disease including cardiac
arrhythmias or diseases due to cardiac structural abnormali
ties may produce cerebral emboli. Atrial ?brillation from
any cause, including rheumatic valvular disease, may result

Since ischemic heart disease is usually asymptomatic
until the eXtent of coronary artery blockage is Well
advanced, preventative measures to control risk factors and
life style patterns associated With the disease are also

recommended. In patients in the symptomatic phase of the
10

in emboli being produced Which can migrate into the arteries
of the brain. Emboli formation and migration can occur as
a result of arteriosclerotic cardiovascular disease and myo

family history of ischemic heart disease, diabetes,
hyperlipidemia, hypertension, obesity and cigarette smok
ing. Life patterns include sedentary lifestyle, psychosocial

cardial infarction. Emboli formation and migration can
occur as a result of arteriosclerotic cardiovascular disease

and myocardial infarction. Emboli formation is also a de?
nite risk for intracardiac surgery and prosthetic valve

disease, meticulous attention to life patterns or risk factors
must be given in an attempt to promote lesion regression or
at least prevent progression. Risk factors include a positive

15

tension and certain personality traits.
Peptide P may be administered to asymptomatic individu
als having one or more risk factors and/or life style patterns

replacement. Heart bypass surgery and angioplasty can
result in the formation of microemboli, Which can migrate

or to individuals already in the symptomatic phase of

into the arteries of the brain and cause a series of occlusions

sion. Additionally, Peptide P may be administered to the
folloWing patients: those having careers that involve the

in a number or arteries, resulting in mental impairment.

ischemic heart disease to reduce or prevent disease progres
20

safety of others (e.g., commercial airline pilots) and that
present With questionable symptoms, suspicious or positive

Cerebral embolism is also the principal complication in the
transplant of arti?cial hearts. Furthermore, the overall risk of
stroke after any type of general surgery is 0.2 to 1 percent.
The vegetations of acute and subacute bacterial endocarditis
can give rise to emboli, Which can occlude a major intrac

noninvasive test results, and in Whom there are reasonable
doubts about the state of the coronary arteries; males Who
25

ranial artery. Thus, When these disease states or surgical
procedures are planned or are happening, Peptide P can be
administered to prevent brain damage due to any resultant
emboli and stroke.
Peptide P can be administered to ameliorate or prevent

are 45 or older and females Who are 55 Will undergo valve
replacement and Who may or may not have clinical evidence

of myocardial ischemia; and those at high risk after myo
cardial infarction because of the recurrence of angina, heart

failure, frequent ventricular premature contractions, or signs
30

ischemic necrosis of the spinal cord. The ischemia may be
caused by an endarteritis of surface arteries leading to

of ischemia in the stress test, to name just a feW. Peptide P
may be administered either separately or in combination

With other cardiac drugs such as nitrates, beta-adrenergic

thrombosis. Atherosclerotic thrombosis of the aorta or dis

blockers, calcium channel antagonists and/or aspirin and

secting aortic aneurysms may cause infarction of the spinal

either separately or in combination With ?brinolytic drugs
such as tissue plasminogen activator (tPA), streptokinase
and urokinase. Use of Peptide P may prolong life and/or

cord (myelomalacia) by occluding nutrient arteries at
cervical, thoracic or lumbar levels, as can paralysis during
cardiac surgery requiring clamping of the aorta for more
than 30 minutes and aortic arteriography. Infarctive or

reduce or eliminate the need for invasive procedures such as

coronary arteriography and coronary artery bypass grafting.
According to the present invention, Peptide P is admin

hemorrhagic vascular lesions of the spinal cord
(hematomyelia) may result in the sudden onset of symptoms

istered to a mammal to treat cerebral or spinal cord ischemia
referable to sensory or motor or both spinal tract lesions. 40 or ischemic heart disease including reperfusion injury. Pep
tide P may be formulated for administration in an aqueous
Peptide P can also be administered to ameliorate or inhibit

based liquid such as phosphate buffered saline to form an
emulsion, or it may be formulated in an organic liquid such
as cyclodeXtrin or dimethylsulfoXide to form a solution. The

damage caused by ischemic heart disease. Ischemic heart
disease is a general term for a spectrum of diseases of

diverse etiology caused by an imbalance betWeen oXygen
supply and demand. The usual cause of the imbalance is

45

ing to an absolute decrease in coronary artery blood ?oW. An
imbalance may also result from nonatheromatous coronary
obstructive lesions such as embolism, coronary ostial steno
sis associated With luetic aortitis, coronary artery spasm, or
very uncommonly an arteritis of the coronary vessels. The
imbalance may also be due to congenital abnormalities of
the coronary circulation, an increase in myocardial oXygen

demands exceeding the supply capabilities in a normal
coronary circulation, a diminished oxygen-carrying capacity
of the blood such as in anemia or in the presence of

tered by any route, but it is preferably administered parenter
ally such as by intravenous, intramuscular, intradermal or
50

A preferred Peptide P dose is in the range of about 0.5

55

Weight of the mammal, or alternatively loWer doses of about
1 mg/kg body Weight of the mammal to about 1000 mg/kg
body Weight of the mammal. The time of administration of
a single dose of Peptide P is preferably up to about four
hours after onset of an ischemic episode. HoWever, Peptide
P may be administered concurrently With the onset of a
ischemic episode or even prior to onset of ischemia and still

or as a consequence of inadequate perfusion pressure due to

hypotension. When ischemic events are transient, they may

produce a therapeutic effect.
Ef?cacy of Peptide P treatment may be evaluated using
noninvasive clinical imaging methods such as magnetic
resonance imaging (MRI) of the affected region to determine

be associated With angina pectoris: if prolonged, they can
lead to myocardial necrosis and scarring With or Without the

clinical picture of acute myocardial infarction. Ischemic
heart disease may be readily diagnosed by one skilled in the
art. There may be predictive changes in the
electrocardiogram, since ischemia alters electrical properties

and displacement of the ST segment. Another important
consequence of myocardial ischemia is electrical instability

intraperitoneal injections.
mg/kg body Weight of the mammal to about 20 mg/kg body

carboXyhemoglobin (e. g., due to cigarette or cigar smoking),

of the heart. Such changes include inversion of the T Wave

peptide-P active ingredient should be present in an effective
amount of about 0.001 Wt. % up to 25.0 Wt. % in such
compositions. The solution or emulsion may be adminis

atherosclerotic obstruction of large coronary arteries, lead

the siZe of the damaged area. In cerebral ischemia, it is also
possible to assess neurologic de?cit by performance on
65

behavioral tests such as cognitive recognition or memory
function such as the National Institutes of Health (NIH)
stroke scale.
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While the speci?c mechanism of Peptide P action on
ischemia is unknown, Peptide P exhibits a speci?c and

Control animals (n=5) received I.V. injections of saline or

1% cyclodextrin. Peptide P treated animals (n=6) received 4
mg/kg of Peptide P 1 hour folloWing middle cerebral antery

reproducible effect on decreasing neurological de?cit and
cerebral infarct volume. This invention Will be further

occlusion (MCAO). At time O, animals Were subjected to 1
hour focal middle cerebral arterial occlusion (MCAO)

appreciated in light of the folloWing example.
The folloWing example is presented to illustrate the

ischemia and 24 hour of reperfusion. Cerebral blood Was

invention but the invention is not considered to be limited
thereto.

prior to ischemia and at 0.5 hour, 1 hour and 2 hours post

assessed by laser-Doppler ?oWmetry With a ?ber optic probe
ischemia. Ischemic volume Was measured and animals Were

EXAMPLE

10

A murine model of ischemia/reperfusion injury Was used
to evaluate the effects of Peptide P on cerebral blood ?oW,
behavioral changes and ischemia infarct volume.
Induction of Ischemia
Ischemia Was induced by transient occlusion of the exter

15

nal carotid artery (ECA). Male ICR mice Weighing about
30—35 g Were anesthetiZed With an intraperitoneal (i.p.)

injection of chloral hydrate (350 mg/kg of body Weight) and
xylaZine (4 mg/kg of body Weight). Rectal temperatures
Were maintained at 3710.5° C. With a heating pad and
incubator. The left femoral artery Was cannulated With a
PE-10 catheter for measurement of arterial blood pressure,

ECA, superior thyroid artery (STA) and occipital artery

side at rest or no spontaneous motor activity (severe).
Evaluation of Treatment
Brain infarct volume Was measured after 1 hour of

ischemia and again at 24 hours after reperfusion. At the
20

desired endpoint, the animal Was euthaniZed. The brain Was
immediately removed and placed into a mouse brain matrix

(ASI, Warren, Mich.) and 2 mm sections Were made. Brain
sections Were stained With 2% 2,3,5-triphenyltetraZolium
chloride (TTC). Infarct siZe Was determined according to the
formula:

pO2, pCO2 and pH.
A midline incision Was made in the skin of the neck and
the left common carotid artery (LCCA) Was exposed. The

assessed for behavior changes using a numerical ranking
from 0 to 3 according to the folloWing criteria: 0=no
observable de?cits (normal); 1=failure to extend right fore
paW upon lifting by the tail (mild); 2=circling to the con
tralateral side (moderate); and 3=leaning to the contralateral

25

(Contralateral volume-ipsilateral undamaged volume)><100/Con—

(OA) Were isolated. The STA and OA Were electrocoagu

tralateral volume

lated using a cautery probe (Baster Hi Temp Cautery, Baxter
Healthcare Corp.) and divided. The base of the ECA Was
secured With a microsurgical clip, then the distal end of the
ECA Was ligated With a 6-0 nylon suture and the ECA Was
cut. A blunted 5-0 blue mono?lament nylon suture Was

to eliminate the effects of edema. Quantitation of contralat
30

placed in the end of the ECA, the surgical clip Was removed,

Statistical analysis of the volume analysis results Was
performed using the Student’s t-test or analysis of variance

then the blunted suture Was advanced into the ECA until
resistance Was detected. The blunted suture Was then tight

ened to prevent both slipping of the internal suture and

35

(ANOVA) folloWed by the Bonferroni test. Statistical sig
ni?cance Was assigned to comparisons of sections from
control versus Peptide P treated animals With p<0.006. Data

bleeding. The suture Was trimmed and the incision Was

sealed by suturing the skin. The suture remained in place for
varying lengths of time up to 24 h. At the desired time,
reperfusion of the brain (restoration of blood How to the
brain) Was accomplished by retreating the suture from the

eral and ipsilateral volumes Was determined by image analy
sis using a Scion Image (NIH Image Version 1.59) modi?ed
by Scion Corp. and Adobe Photoshop 2.0.1.

Were expressed as mean1standard error of the mean (SEM).

Prior to Peptide P treatment, there Were no signi?cant

Mean arterial blood pressure (MABP), pO2, pCO2 and

differences in MABP, pO2, pCO2, pH or rectal temperature
betWeen control animals and deltorphin-treated animals.
Upon induction of ischemia by middle cerebral arterial

pH Were measured before occlusion, 10 min after occlusion
and 30 min after reperfusion. Cerebral blood How Was

25% reduction in cerebral blood ?oW Which Was sustained

40

ECA.

monitored by laser-Doppler ?oWmetry With a ?ber optic
probe placed 2 mm posterior and 6 mm lateral to the bregma
on the ipsilateral hemisphere of the brain.

occlusion, both control and Peptide P-treated animals had a
45

Treatment

for 1 hour during the ischemia. After cessation of ischemia,
cerebral blood ?oW returned to baseline levels Within 0.5
hour. Post ischemia, there Were no signi?cant differences in

MABP, pO2, pCO2, pH or rectal temperature betWeen

The test compound Was Peptide P (Tyr-D-Ala-Phe-Ala

Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile
NH2). For analysis of the test compound, a solution of the
test compound in saline or 1% cyclodextrin Was prepared.
The test compound in solution Was administered by I.V.
injection at multiple doses prior to or up to 4 hours folloWing

ischemic injury.

control animals and deltophin-treated animals. There Was,
50

hoWever, a signi?cant (<0.05) decrease in neurological
de?cits from Peptide P treated animals (0.44111) versus

control animals (1.5510.19). Additionally, infarct volume
Was also signi?cantly reduced by 59% in Peptide P-treated
animals (2414.8 mm3) compared to control animals (5817.2
mm3) after 24 h of reperfusion, see FIG. 1, Table 1 & 2.
TABLE 1

Peptide-P (Pep-P)
Mouse strain/C57
No.
Sex

Ischemia Time

Reperfusion Time
Cross Section Area 1
Cross Section Area 2

Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P
1
M

2
M

3
M

4
M

5
M

6
M

1hr 1hr 1hr 1hr 1hr 1hr
24 hr 24 hr 24 hr 24 hr 24 hr 24 hr
10.43 9.53 10.74 13.46 11.00 11.71
17.91 16.64 17.44 19.06 18.11 18.8

Total Average

US 6,967,192 B2
TABLE l-continued
Peptide-P (Pep-P)
Mouse strain/C57

Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P

Cross Section Area 3
Cross Section Area 4
Total Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged Cross Section Area
Damaged %
Corrected Volume

19.77 19.62 19.46 20.7 21.19 21.3
20.43 18.93 19.26 19.73 20.85 20.73
68.54 64.72 66.9 72.95 71.15 72.54
3.69 0
1.42 1.89 0
0.27
5.66 0.32 1.38 3.27 4.59 1.8
6.47 1.12 2.63 7.23 2.22 5.15
1.84 1.11 3.06 5.54 6.11 4.46
17.66 2.55 8.49 17.93 12.92 11.68
25.77 3.94 12.69 24.58 18.16 16.10
35.32 5.10 16.98 35.86 25.84 23.36

1
2
3
4

Total Average

416.8

68.77 1 1.4%

71.23 11.87 1 2.4%
101.24 16.87 1 3.3%
142.46 23.74 1 4.8% mm3

Corrected Volume (mm3) = Damaged Cross Section Area x 2 mm section

After 1 hr ischemia mice Were injected With 100 #1 Peptide-P (4 mg/Kg)

TABLE 2
Saline

Mouse strain/C57
No.
Sex
Ischemia Time

Reperfusion Time
Cross Section Area 1
Cross Section Area 2
Cross Section Area 3
Cross Section Area 4
Total Cross Section Area
Damaged Cross Section Area 1

Damaged Cross Section Area 2
Damaged Cross Section Area 3
Damaged Cross Section Area 4
Damaged Cross Section Area
Damaged %
Corrected Volume

Saline

Saline

Saline

Saline

Saline

1
M
1 hr

2
M
1 hr

3
M
1 hr

4
M
1 hr

5
M
1 hr

24 hr
14.81
22.52
25.24
24.51

24 hr
14.65
22.39
25.45
24.05
86.54
4.49

24 hr
12.55
19.52
21.84
21.54

24 hr
13.18
20.68
23.51
24.98

24 hr
15.35
22.08
24.77
23.81

75.45

82.35

86.01

417.43 83.49 1 2.2%

1.77
2.42
7.65
9.03
20.87
27.66
41.74

1.02
2.21
5.79
11.21
20.23
24.57
40.46

4.83
8.81
9.52
8.26
31.42
36.53
62.84

144.95 28.99 1 3.6%
172.18 34.45 + 3.6%
289.9 57.98 1 7.2% mm3

87.08

6.58
9.7
11.86
10.02
38.16
43.82
76.32

6.86
10.7
12.22
34.27
39.60
68.54

Total

Average

Corrected Volume (mm3) = Damaged Cross Section Area x 2 mm section

After 1 hr ischemia mice Were injected With 100 #1 physiological saline
40

4. The method of claim 1, Wherein said Peptide P is

Identi?cation of a novel seventeen amino acid Peptide,
Peptide P and a method for treating cerebral or spinal cord

administered up to four hours subsequent to onset of
ischemia.

ischemia or ischemic heart disease including reperfusion

injury by Peptide P administration is thus disclosed. Peptide
P, SEQ ID NO:1 is formulated for biocompatible adminis
tration in a preferred dose in the range of about 0.5—20

45

mg/kg, or alternatively 1—1000 mg/kg body Weight of the
animal. The Peptide P dose may be administered up to four
hours after the onset of an ischemic attack. Alternatively, the

sion.

50

8. The method of claim 1, Wherein said Peptide P is

It should be understood that the embodiments of the

administered at a concentration in the range of about 0.5—20

present invention shoWn and described in the speci?cation

mg/kg of body Weight of said mammal.
55

mg/kg of body Weight of said mammal.
10. The method of claim 1, Wherein said Peptide P is

departing from the spirit of the invention and scope of the

administered to treat cerebral ischemia.

folloWing claims.
60

11. The method of claim 1, Wherein said Peptide P is
administered to treat ischemic heart disease and/or reperfu

sion injury.

1, in a pharmaceutically acceptable carrier.
2. The method of claim 1 Wherein said Peptide P is
administered prior to onset of ischemia.
3. The method of claim 1, Wherein said Peptide P is
administered 24 hours prior to the onset of ischemia.

9. The method of claim 1, Wherein said Peptide P is
administered at a concentration in the range of 1—1000

these embodiments may be made or restored to Without

What is claimed is:
1. Amethod of treating ischemia in a mammal comprising
administering an effective amount of Peptide P SEQ ID NO:

7. The method of claim 1, Wherein said Peptide P is

administered parenterally.

of an ischemic event.

are only preferred embodiments of the inventors Who are
skilled in the art and thus are not limiting in any Way.
Therefore various changes, modi?cations or alterations to

ischemia.
6. The method of claim 1, Wherein said Peptide P is
administered in a carrier formulation selected from the
group consisting of a solution, an emulsion and a suspen

Peptide P dose may be administered prophylactically in
patients at risk for an ischemic attack such as, for example,
prior to surgery. Peptide P administration reduces the effect

5. The method of claim 1, Wherein said Peptide P is
administered substantially concurrently With onset of

65

12. The method of claim 1, Wherein said Peptide P is
administered to treat spinal cord ischemia.
13. A method for treating cerebral ischemia in a mammal
comprising administering a pharmaceutically effective con
centration of a Peptide P, SEQ ID NO: 1.

US 6,967,192 B2
9

10

14. A method of reducing effects of an ischemic episode
17. The method of claim 13, Wherein the said Peptide P is
in a mammal comprising administering a pharmaceutically
administered substantially concurrently With onset of
effective concentration of a Peptide P, SEQ ID NO: 1.
ischemia_
15. The method of 14, Wherein said Peptide P is admin
istered up to four hour subsequent to said ischemic episode. 5
16. The method of claim 14, Wherein said Peptide P is
administered prior to said ischemic episode.
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